In addition, Tumor Immune Estimation Resource 2.0 (TIMER 2.0) and the Human Protein Atlas also showed a tendency towards poor prognosis in patients with high apelin levels, when analyzing the associations between the expression levels of apelin gene and survival outcomes in TCGA: TIMER 2.0 analyzed 471 patients with skin cutaneous melanoma (p = 0.065); the Human Protein Atlas studied 102 patients (p = 0.047; data not shown)56,57. The gene discussed is APLN; the disease is cutaneous melanoma.